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Figure A. Flow chart summarizing search strategy for potential studies, updated regularly until July 
2010. 
 
4834 potentially relevant citations identified and screened in 
electronic databases, publication lists and a registry of 
genetic association studies available
4123 citations excluded on basis of title
711 abstracts identified and scanned
525 articles excluded on basis of abstract
55 potentially relevant articles identified 
28 articles excluded due to duplicate 
information
36 relevant studies from 27 articles identified through 
literature searches
15 unpublished studies identified through 
the registry approach and direct contact 
with study PIs.
186 full-text articles retrieved for more detailed evaluation
131 articles excluded due to inappropriate 
study design, including 56 review articles 
47 studies contacted through literature searches and 
registry approach (including the Emerging Risk Factors 
Collaboration) agreed to share IPD in the CCGC





 Excluded studies, including the Physician’s Health Study (PHS, Zee, R. Atherosclerosis 2002;162(1):217-219); Women’s 
Genome Health Study (WGHS, Ridker, P. Clin Chem 2008;54(2):249-55); Pravastatin Inflammation / CRP Evaluation trial 
(PRINCE; Suk, H. Atherosclerosis 2005;178(1):139-145) and the Beijing Atherosclerosis Study (BAS, Chen, J. J Mol Med. 
2005;83(1):72-78) comprising less than 1000 cases of CHD. 
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Figure B. Geometric mean CRP levels in according to study and design in 36 studies with CRP 















































































































































































* These studies provided tabular data. Overall mean loge CRP (SD) was 0.63 (1.057).  SD = standard deviation; -W = European 
descent populations; -B = African descent populations; study abbreviations are listed in appendix 2.  
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Individual participant data RR (95% CI)
rs1800947
















































= 0.0% (95% CI 0.0, 48.9%)
P-value for heterogeneity = 0.623
I2 = 63.9% (95% CI 47.7, 75.1%); P-value for heterogeneity < 0.001
I2 = 0.0% (95% CI 0.0, 35.8%)
P-value for heterogeneity = 0.921I2 = 36.6% (95% CI 3.1, 58.4%); P-value for heterogeneity = 0.020
I2 = 0.0% (95% CI 0.0, 40.2%)
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0.99 (0.90, 1.08)
0.76 (0.53, 1.10)

























































































1.2 .4 .6 .8 1.5 2 3
I2 = 26.5% (95% CI 0.0, 49.8%)
P-value for heterogeneity = 0.060
 
 
CI indicates confidence interval. The sizes of data markers are proportional to the inverse of the variance of the risk ratios; 
analyses were stratified, where appropriate, or adjusted for sex, trial arm, and ethnicity. -W = European descent population; -B = 
African descent population; study abbreviations are listed in appendix 2. 
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 Constant SNP Time 
Interaction between SNP 
and time 
 Beta (standard error) Beta (standard error) Beta (standard error) Beta (standard error) 
rs3093077 -1.469(0.083) 0.214 (0.017) 0.017 (0.008) <0.001 (0.003) 
rs1205 -1.666(0.091) 0.176 (0.008) 0.022 (0.008) <0.001 (0.001) 
rs1130864 -0.496 (0.277) 0.125 (0.006) 0.020 (0.009) 0.001 (0.001) 
rs1800947 -1.366 (0.479) 0.271 (0.016) 0.020 (0.007) 0.007 (0.003) 
 
Dashed lines represent 95% confidence intervals; analyses were stratified, where appropriate, or adjusted for sex, trial arm, and ethnicity. 21,913 repeat measures of circulating CRP were available in 
20,912 participants. Mean duration between repeat measurements was 2.9 (SD 1.9) years.  Study-specific estimates of regression of loge CRP on SNP, time, SNP*time adjusted for sex and ethnicity 
were combined using multivariate random effects meta-analysis. The SNP-CRP association is plotted over time using the combined regression coefficients. 
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Estimates presented are based on a random-effects meta-analysis of study-specific associations of haplotypes with a panel of risk factors, assuming an additive model for haplotype effects, relative to 
reference haplotype 1; analyses were stratified, where appropriate, or adjusted for sex and trial arm; analyses are limited to European descent populations due to insufficient data to determine 
relevant haplotypes in African or Asian descent populations; CI = confidence interval; BP = blood pressure; HDL = high density lipoprotein, LDL = low density lipoprotein 
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Figure F. Estimates of association of each haplotype with usual levels of loge CRP and coronary disease risk, compared to carrying two copies of reference 
















0-0.5 -0.4 -0.3 -0.2 -0.1 0.1 0.2
Change in mean loge CRP per copy of haplotype




Risk ratio (95% CI) for CHD per copy of haplotype
compared to reference haplotype 1
0.24 -0.10 (-0.12, -0.08)
Frequency
(1) T / C / T / G
(3) G / C / C / G
(4) T / T / C / G
(5) T / T / C / C
(6) ? / C / C / G §
(7) T / T / C / ? ‡
(2) T / C / C / G
Haplotype
0.13 -0.21 (-0.24, -0.17)









An additive haplotype model was used to estimate the effect of each haplotype relative to 2 copies of haplotype 1. CI = confidence intervals, depicted by error bars. § Haplotype 6 comprises 
participants who cannot be allocated to haplotypes 2 or 3 due to insufficient data on the following SNPs: rs3093077, rs3093068, rs3091244 and rs2794521. ‡ Haplotype 7 comprises participants who 
cannot be allocated to haplotypes 4 or 5 due to insufficient data on the rs1800947 SNP.  
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Figure G. Study-specific estimates for CRP and coronary heart disease risk per additional copy of 
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Risk ratio for CHD per additional copy of haplotype 
(compared to two copies of haplotype 1)
Change in loge CRP per additional copy of haplotype 
(compared to two copies of haplotype 1)
I2 = 0.0% (95% CI 0.0 – 41.3%)
P-value for heterogeneity = 0.665
I2 = 0.0% (95% CI 0.0 – 41.3%)
P-value for heterogeneity = 0.996
I2 = 0.0% (95% CI 0.0 – 43.2%)
P-value for heterogeneity = 0.513
I2 = 0.0% (95% CI 0.0 – 41.3%)
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I2 = 7.0% (95% CI 0.0 – 39.3%)
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Random effects
Fixed effect
I2 = 0.0% (95% CI 0.0 – 47.0%)
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(compared to two copies of haplotype 1)
Change in loge CRP per additional copy of haplotype 
(compared to two copies of haplotype 1)
I2 = 43.7% (95% CI12.5 – 63.7%)
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I2 = 0.0% (95% CI 0.0 – 41.3%)
P-value for heterogeneity = 0.885
I2 = 0.0% (95% CI 0.0 – 47.0%)
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I2 = 0.0% (95% CI 0.0 – 46.2%)
P-value for heterogeneity = 0.948
I2 = 0.0% (95% CI 0.0 – 41.3%)










































































































































































1.2 .4 .6 .8 1.5 2 3
I2 = 20.2% (95% CI 0.0 – 48.3%)
P-value for heterogeneity = 0.154
 
 
Analyses limited to participants of European descent. The sizes of data markers are proportional to the inverse of the variance of 
the loge risk ratios; analyses were stratified, where appropriate, or adjusted for sex and trial arm. CI = confidence interval; RR = 
risk ratio; study abbreviations are listed in appendix 2. 
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0.6 1.2 2.4 4.8 9.6
Geometric mean CRP (mg/L)
Adjusted for age, sex, ethnicity and conventional risk factors*




* Conventional risk factors include: systolic blood pressure, history of diabetes mellitus, body mass index, smoking status, HDL, 
non-HDL and triglycerides. Analyses for coronary heart disease were based on data from 71,005 participants (including 5028 
cases) from 21 studies with complete data on CRP, age, sex and conventional risk factors. Sizes of data markers are proportional 
to the inverse of the variance of the loge RRs. The y-axis is shown on a log scale. Referent groups are the lowest deciles of CRP. 
































































































































0.5 1 2 4 8
Risk ratio (95% CI) for CHD per 1-SD higher log CRP
I2 = 35% (95% CI: 0 - 62%)




Usual levels of CRP adjusted for age, sex and usual levels of systolic blood pressure, smoking status, history of diabetes 
mellitus, body mass index, high density lipoprotein cholesterol (HDL-C), non-HDL-C and loge triglyceride. The sizes of data 
markers are proportional to the inverse of the variance of the loge risk ratios. CI = confidence interval; study abbreviations are 
listed in appendix 2. 
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Study-specific risk ratios were adjusted for age, systolic blood pressure, smoking status, history of diabetes, body mass index, 
high density lipoprotein cholesterol (HDL-C), non-HDL-C and loge triglyceride and stratified, where appropriate, for sex, ethnicity 
and trial arm. Study-specific estimates were combined using random effects multivariate meta-analysis. Studies with fewer than 
10 cases were excluded from the analyses. CI = confidence interval. The sizes of data markers are proportional to the inverse of 
the variance of the loge risk ratios. 
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10.1 0.5 1.5 2 3 4 8
Retrospective studies
Prospective studies
RR (95% CI) for CHD per 1-SD higher genetically predicted loge CRP
I2 = 0.0% (95% CI 0.0 – 36.6%)
P-value for heterogeneity = 0.537
Risk ratio (95% CI)
SNP – based approach
ROTTERDAM
EPICNOR


























































10.1 0.5 1.5 2 3 4 8
I2 = 0.4% (95% CI 0.0 – 42.8%)
P-value for heterogeneity = 0. 457
Retrospective studies
Prospective studies Risk ratio (95% CI)
Haplotype – based approach
Random effects
Fixed effect




Study-specific estimates are only shown for studies with concomitant data on CRP variants, circulating CRP and CHD. Summary estimates presented here include data from additional studies that did 
not provide concomitant data. Analyses were stratified, where appropriate, or adjusted for sex, trial arm, and ethnicity. The sizes of data markers are proportional to the inverse of the variance of the 
risk ratios. CI = confidence interval. -W = European descent populations; -B = African descent populations, -A = Asian descent population; study abbreviations are listed in appendix 2. 
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SNPs are coded for increased levels of circulating loge CRP; Associations are presented for each genotype compared to a reference genotype with zero copies of the risk allele.  
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10.75 0.9 0.95 1.05 1.1
Per-allele risk ratio for CHD (95% CI)
19 / 15,016 / 95,861 
40 / 36,229 / 162,029 
40 / 33,567 / 149,595 
28 / 27,364 / 83,557 





*Frequency of allele for increased levels of circulating loge CRP (ie, risk allele). Associations are presented per additional copy of the risk allele. ‡ For SNP – CHD associations; Studies with fewer 
than 10 cases or fewer than 50 participants were excluded from analyses. Study-specific estimates were stratified, where appropriate, by sex, ethnicity and trial arm and combined using random 
effects models. Maximum available data on genetic variants, circulating CRP and coronary heart disease were used for analyses; sensitivity analyses restricted to participants with data on CRP 
SNPs, circulating CRP and coronary disease did not differ from the current analyses. CI = confidence intervals, depicted by error bars.  
 
 
 
 
